STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ case
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Supreme Court unanimously ruled that Hikma Pharmaceuticals did not infringe patents held by Amarin.
- Supreme Court decision overturned a lower‑court ruling that had favored Amarin.
- Generic drugmakers argued that a ruling for Amarin would discourage production of low‑cost versions and keep prescription‑drug prices high.
- Skinny labeling lets generic firms seek approval for a limited indication of a drug to avoid patent‑infringement suits.
Why it matters: Generic manufacturers win, while Amarin loses a key enforcement tool; the decision helps keep low‑cost generics on the market, reducing prescription‑drug prices and limiting the brand‑name maker’s ability to block competition.
